Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccines against dangerous pathogens.

E D Williamson1, R W Titball

  • 1DSTL, Chemical and Biological Sciences, Porton Down, Salisbury, UK.

British Medical Bulletin
|August 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis.

Microbiology spectrum·2023
Same author

Role of RelA and SpoT in Burkholderia pseudomallei survival, biofilm formation and ceftazidime tolerance during nutritional stress.

Tropical biomedicine·2021
Same author

Vaccines for emerging pathogens: from research to the clinic. Part two.

Clinical and experimental immunology·2019
Same author

Antibody-mediated protection against MERS-CoV in the murine model.

Vaccine·2019
Same author

Burkholderia thailandensis strain E555 is a surrogate for the investigation of Burkholderia pseudomallei replication and survival in macrophages.

BMC microbiology·2019
Same author

CD200R deletion promotes a neutrophil niche for Francisella tularensis and increases infectious burden and mortality.

Nature communications·2019
Same journal

Human health in relation to visible, functional, and accessible green space: a systematic review and narrative synthesis of the 3 + 30 + 300 guideline.

British medical bulletin·2026
Same journal

Muscle herniae in exercise-induced leg pain: diagnostic pitfalls and the 'repair paradox'.

British medical bulletin·2026
Same journal

Scaffolds and platelet concentrates in bone regenerative medicine: applications, mechanisms, and future approaches.

British medical bulletin·2026
Same journal

Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses.

British medical bulletin·2026
Same journal

Enhancing bone healing through osteogenic medium components: biological roles, mechanisms, and clinical applications.

British medical bulletin·2026
Same journal

Moral injury in healthcare workers: causes & interventions.

British medical bulletin·2026
See all related articles

Developing vaccines for dangerous pathogens (category 3 and 4) is challenging. This research explores vaccine development approaches, emphasizing animal models and surrogate markers for efficacy testing.

Area of Science:

  • Pathogen research
  • Vaccine development
  • Biosecurity

Background:

  • Dangerous pathogens are classified as category 3 or 4 by the UK Health and Safety Executive.
  • Developing vaccines for these pathogens presents significant safety challenges.
  • Ethical considerations preclude direct human efficacy testing of candidate vaccines.

Purpose of the Study:

  • To discuss various approaches for developing candidate vaccines against dangerous pathogens.
  • To explore the impact of genome sequencing on accelerating vaccine research and development (R&D).
  • To highlight the importance of animal models and surrogate markers in vaccine efficacy assessment.

Main Methods:

  • Review of existing and novel vaccine development strategies for high-containment pathogens.

Related Experiment Videos

  • Analysis of the role of genomic technologies in pathogen characterization and vaccine design.
  • Evaluation of animal models for preclinical assessment of vaccine safety and immunogenicity.
  • Development and validation of surrogate markers for predicting vaccine efficacy.

    • Main Results:

    • Genome sequencing can significantly reduce the R&D timeline for novel vaccines.
    • Animal models are crucial for demonstrating vaccine efficacy in the absence of human trials.
    • Surrogate markers, when correlated with protection in animal models, aid in efficacy assessment.

    Conclusions:

    • A multi-faceted approach combining advanced technologies and rigorous preclinical testing is essential for developing vaccines against dangerous pathogens.
    • The use of validated surrogate markers is critical for advancing vaccine candidates through the development pipeline.
    • Continued innovation in vaccine R&D is vital for global health security.